ArticleBMC medicine2020
Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study.
Article in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Aspirin and atorvastatin augmentation treatment in patients with major affective disorders and inflammatory dysregulation: a 12-week randomised Placebo-controlled study.Acta neuropsychiatrica · 2026Trial
- Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study.Psychopharmacology · 2022Trial
- Suicidal ideation and interrelated psychiatric disturbances in rheumatoid arthritis: Evidence from a Vietnamese cohort.PloS one · 2026Article
- Machine learning-based prediction of anxiety disorders using blood metabolite and social trait data from the UK Biobank.Brain, behavior, & immunity - health · 2025Article
- Molecular mechanisms and clinical value of the correlation between depression and cancer.Medical oncology (Northwood, London, England) · 2025Review
- Mechanism of N6-Methyladenosine Modification in the Pathogenesis of Depression.Molecular neurobiology · 2025Review
- The Interplay of Chronic Stress and Cancer: Pathophysiology and Implications for Integrated Care.Cancer reports (Hoboken, N.J.) · 2025Review
- Comprehensive view of suicide: A neuro-immune-endocrine approach.World journal of psychiatry · 2025Review
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025Review
- The Mind Body Connection in Dermatologic Conditions: A Literature Review.Journal of cutaneous medicine and surgery · 2023Review
- Effect of Cigarette Smoke Exposure and Aspirin Treatment on Neurotransmitters' Tissue Content in Rats' Hippocampus and Amygdala.Metabolites · 2023Article
- Association between WHO First-Step Analgesic Use and Risk of Breast Cancer in Women of Working Age.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders.Advances in experimental medicine and biology · 2023Review
- Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Incidence of Depression Among Older Cancer Survivors With Osteoarthritis: A Machine Learning Analysis.Cancer informatics · 2023Article
- Aspirin reverts lipopolysaccharide-induced learning and memory impairment: first evidence from an invertebrate model system.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- A network pharmacology approach to predict potential targets and mechanisms of "Annals of medicine · 2022Article
- Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression.Brain sciences · 2022Review
- Mechanism of chronic stress to promote tumor development and the intervention.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Are E-values too optimistic or too pessimistic? Both and neither!International journal of epidemiology · 2022Article
- NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundCancer patients have a highly increased risk of psychiatric disorders following diagnosis, compared with cancer-free individuals. Inflammation is involved in the development of both cancer and psychiatric disorders. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in the subsequent risk of psychiatric disorders after cancer diagnosis is however unknown.
methodsWe performed a cohort study of all patients diagnosed with a first primary malignancy between July 2006 and December 2013 in Sweden. Cox proportional hazards models were used to assess the association of NSAID use during the year before cancer diagnosis with the risk of depression, anxiety, and stress-related disorders during the first year after cancer diagnosis.
resultsAmong 316,904 patients identified, 5613 patients received a diagnosis of depression, anxiety, or stress-related disorders during the year after cancer diagnosis. Compared with no use of NSAIDs, the use of aspirin alone was associated with a lower rate of depression, anxiety, and stress-related disorders (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.81 to 0.97), whereas the use of non-aspirin NSAIDs alone was associated with a higher rate (HR, 1.24; 95% CI, 1.15 to 1.32), after adjustment for sociodemographic factors, comorbidity, indications for NSAID use, and cancer characteristics. The association of aspirin with reduced rate of depression, anxiety, and stress-related disorders was strongest for current use (HR, 0.84; 95% CI, 0.75 to 0.93), low-dose use (HR, 0.88; 95% CI, 0.80 to 0.98), long-term use (HR, 0.84; 95% CI, 0.76 to 0.94), and among patients with cardiovascular disease (HR, 0.81; 95% CI, 0.68 to 0.95) or breast cancer (HR, 0.74; 95% CI, 0.56 to 0.98).
conclusionPre-diagnostic use of aspirin was associated with a decreased risk of depression, anxiety, and stress-related disorders during the first year following cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.